17
Dosing Frequency Comments
†
Initial dose followed
by second dose in 3
months, then every
6 months thereaer
• Subcutaneous agent administered by a health care professional
• Expected LDL-C reduction: 48%–52%
‡
• CVOT in progress
Once or twice daily • Oral agents
• CVOT evidence from 1 trial demonstrating cardiovascular
event reduction in primary prevention men as monotherapy
• Nonsystemic, add-on to statin therapy or in patients with
statin-intolerance
• Expected LDL-C reduction: 10%–27%
‡
• Gastrointestinal side effects may limit use
• Both LDL-C lowering and incidence of side effects are dose
related
• May increase serum TG levels; avoid if TG ≥300 mg/dL
Once or twice daily
Once or multiple
times daily
Once daily • Oral agent
• Expected LDL-C reduction: 40%–50%
‡
• Only available through a restricted program; several adverse
reactions (including hepatotoxicity due to hepatic steatosis
exacerbated by concomitant ethanol intake, as well as
steatorrhea) and drug-drug interactions
• Daily vitamin E, linoleic acid, alpha-linolenic acid, EPA, and
DHA supplements are needed to mitigate reduced absorption
of fat-soluble vitamins/fatty acids
• Multiple potential drug interactions associated with
CYP3A4 metabolism
Every 4 weeks • Intravenously administered agent
• Works through an LDL receptor-independent pathway
• Expected LDL-C reduction: 49%
‡
